semaglutide compunding | NextGenRx Compound Pharmacy Semaglutide Patient Safety Updates |

They are adding cagrilintide

While side effects like gastroparesis and SIBO can be challenging, they dont have to derail your progress

GLP-1 receptor agonists mimic a hormone called glucagon-like peptide-1 that your body produces naturally in the gut after eating

The FDA has also approved Wegovy for adolescents aged 12 years and older who have obesity, defined as: a BMI at or above the 95th percentile for age and sex, based on CDC growth charts Must weigh at least 60 kg (132 lbs) Administered as a once-weekly subcutaneous injection Must be used in conjunction with a reduced-calorie diet and increased physical activity If an adolescent does not achieve at least a 5% reduction in BMI after 12 weeks on the 2.4 mg or maximum tolerated dose, treatment should be discontinued and re-evaluated In March 2024, the FDA approved Wegovy to reduce the risk of cardiovascular death, stroke, and heart attack in adults with cardiovascular disease and either obesity or overweight

Healthgevitys formulation includes an optimal ratio of salcaprozate sodium to our active ingredients

Prices available for patients who are already prescribed a GLP-1 medication but need to access support for their journey to health and well-being